Praxis Halts Vormatrigine Trial Enrollment After Mixed Phase 2/3 Results — Praxis Precision Medicines, Inc.

Event summary

Praxis Precision Medicines' Phase 2/3 POWER1 study for vormatrigine in highly refractory focal onset seizures failed to meet its primary endpoint.
Secondary endpoint (50% response rate) was achieved, with more pronounced seizure reduction at the higher 30 mg dose.
Vormatrigine was well-tolerated with less than 10% adverse event-related discontinuations.
90% of vormatrigine patients transitioned to the open-label extension study.
Praxis is pausing enrollment in the POWER2 study to reassess the vormatrigine program.

The big picture

Praxis's decision to pause vormatrigine's POWER2 study enrollment highlights the challenges in developing next-generation epilepsy treatments. While the drug showed promising secondary efficacy signals and a strong safety profile, the primary endpoint miss raises questions about its commercial potential. This development comes as Praxis continues to advance its diversified CNS portfolio, with multiple late-stage product candidates in both epilepsy and movement disorders.

What we're watching

Development Strategy: Whether Praxis can identify a viable path forward for vormatrigine after the mixed POWER1 results.
Clinical Execution: The pace at which Praxis can reassess and potentially modify the POWER2 study design.
Portfolio Prioritization: How the vormatrigine setback may impact Praxis's focus on preparing for relutrigine and ulixacaltamide launches.